Effect of metoclopramide treatment on thyrotropin and prolactin levels in sick neonates

F. Ruppert, E. Sulyok, I. Sárkány, K. Zámbó, I. F. Csaba

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The present study was carried out to define whether dopaminergic mechanisms contribute to the regulation of thyrotropin (TSH) and prolactin PRL release in the immediate neonatal period. 14 full-term neonates with a mean birth weight of 3,240 g and a mean gestational age of 39.1 weeks were administered metoclopramide (MTC), a specific dopamine antagonist, in a dose of 0.1 mg/kg/day to treat delayed gastric emptying, regurgitation and abdominal distension. Prior to and after 3-day MTC administration, blood samples were taken to determine serum TSH and PRL levels using a radioimmunoassay method. It has been demonstrated that in response to MTC administration PRL increased significantly from 4,010 ± 383 to 5,478 ± 441 mU/1 (p <0.01), while TSH showed only a tendency to rise independent of the pretreatment hormone levels (from 2.85 ± 0.44 to 3.06 ± 0.38 mU/L. In healthy control infants and in those infants with similar functional gastrointestinal disturbances who were treated without MTC, scrum PRL levels fell significantly from days 3-4 to days 6-7, scrum TSH, triiodothyronine and free thyroxine, however, remained unaltered. It is concluded that dopaminergic inhibitory mechanisms may.be involved in the control of pituitary PRL and TSH release already in the neonatal period.

Original languageEnglish
Pages (from-to)141-146
Number of pages6
JournalNeonatology
Volume50
Issue number3
DOIs
Publication statusPublished - 1986

Fingerprint

Metoclopramide
Thyrotropin
Prolactin
Newborn Infant
Laryngopharyngeal Reflux
Dopamine Antagonists
Gastric Emptying
Triiodothyronine
Therapeutics
Thyroxine
Birth Weight
Gestational Age
Radioimmunoassay
Hormones
Serum

Keywords

  • Full-term neonates
  • Metoclopramide
  • Prolactin
  • Thyrotropin

ASJC Scopus subject areas

  • Developmental Biology
  • Pediatrics, Perinatology, and Child Health

Cite this

Effect of metoclopramide treatment on thyrotropin and prolactin levels in sick neonates. / Ruppert, F.; Sulyok, E.; Sárkány, I.; Zámbó, K.; Csaba, I. F.

In: Neonatology, Vol. 50, No. 3, 1986, p. 141-146.

Research output: Contribution to journalArticle

Ruppert, F. ; Sulyok, E. ; Sárkány, I. ; Zámbó, K. ; Csaba, I. F. / Effect of metoclopramide treatment on thyrotropin and prolactin levels in sick neonates. In: Neonatology. 1986 ; Vol. 50, No. 3. pp. 141-146.
@article{d0d84672099d4ea497d86cf2ad150dd8,
title = "Effect of metoclopramide treatment on thyrotropin and prolactin levels in sick neonates",
abstract = "The present study was carried out to define whether dopaminergic mechanisms contribute to the regulation of thyrotropin (TSH) and prolactin PRL release in the immediate neonatal period. 14 full-term neonates with a mean birth weight of 3,240 g and a mean gestational age of 39.1 weeks were administered metoclopramide (MTC), a specific dopamine antagonist, in a dose of 0.1 mg/kg/day to treat delayed gastric emptying, regurgitation and abdominal distension. Prior to and after 3-day MTC administration, blood samples were taken to determine serum TSH and PRL levels using a radioimmunoassay method. It has been demonstrated that in response to MTC administration PRL increased significantly from 4,010 ± 383 to 5,478 ± 441 mU/1 (p <0.01), while TSH showed only a tendency to rise independent of the pretreatment hormone levels (from 2.85 ± 0.44 to 3.06 ± 0.38 mU/L. In healthy control infants and in those infants with similar functional gastrointestinal disturbances who were treated without MTC, scrum PRL levels fell significantly from days 3-4 to days 6-7, scrum TSH, triiodothyronine and free thyroxine, however, remained unaltered. It is concluded that dopaminergic inhibitory mechanisms may.be involved in the control of pituitary PRL and TSH release already in the neonatal period.",
keywords = "Full-term neonates, Metoclopramide, Prolactin, Thyrotropin",
author = "F. Ruppert and E. Sulyok and I. S{\'a}rk{\'a}ny and K. Z{\'a}mb{\'o} and Csaba, {I. F.}",
year = "1986",
doi = "10.1159/000242591",
language = "English",
volume = "50",
pages = "141--146",
journal = "Neonatology",
issn = "1661-7800",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Effect of metoclopramide treatment on thyrotropin and prolactin levels in sick neonates

AU - Ruppert, F.

AU - Sulyok, E.

AU - Sárkány, I.

AU - Zámbó, K.

AU - Csaba, I. F.

PY - 1986

Y1 - 1986

N2 - The present study was carried out to define whether dopaminergic mechanisms contribute to the regulation of thyrotropin (TSH) and prolactin PRL release in the immediate neonatal period. 14 full-term neonates with a mean birth weight of 3,240 g and a mean gestational age of 39.1 weeks were administered metoclopramide (MTC), a specific dopamine antagonist, in a dose of 0.1 mg/kg/day to treat delayed gastric emptying, regurgitation and abdominal distension. Prior to and after 3-day MTC administration, blood samples were taken to determine serum TSH and PRL levels using a radioimmunoassay method. It has been demonstrated that in response to MTC administration PRL increased significantly from 4,010 ± 383 to 5,478 ± 441 mU/1 (p <0.01), while TSH showed only a tendency to rise independent of the pretreatment hormone levels (from 2.85 ± 0.44 to 3.06 ± 0.38 mU/L. In healthy control infants and in those infants with similar functional gastrointestinal disturbances who were treated without MTC, scrum PRL levels fell significantly from days 3-4 to days 6-7, scrum TSH, triiodothyronine and free thyroxine, however, remained unaltered. It is concluded that dopaminergic inhibitory mechanisms may.be involved in the control of pituitary PRL and TSH release already in the neonatal period.

AB - The present study was carried out to define whether dopaminergic mechanisms contribute to the regulation of thyrotropin (TSH) and prolactin PRL release in the immediate neonatal period. 14 full-term neonates with a mean birth weight of 3,240 g and a mean gestational age of 39.1 weeks were administered metoclopramide (MTC), a specific dopamine antagonist, in a dose of 0.1 mg/kg/day to treat delayed gastric emptying, regurgitation and abdominal distension. Prior to and after 3-day MTC administration, blood samples were taken to determine serum TSH and PRL levels using a radioimmunoassay method. It has been demonstrated that in response to MTC administration PRL increased significantly from 4,010 ± 383 to 5,478 ± 441 mU/1 (p <0.01), while TSH showed only a tendency to rise independent of the pretreatment hormone levels (from 2.85 ± 0.44 to 3.06 ± 0.38 mU/L. In healthy control infants and in those infants with similar functional gastrointestinal disturbances who were treated without MTC, scrum PRL levels fell significantly from days 3-4 to days 6-7, scrum TSH, triiodothyronine and free thyroxine, however, remained unaltered. It is concluded that dopaminergic inhibitory mechanisms may.be involved in the control of pituitary PRL and TSH release already in the neonatal period.

KW - Full-term neonates

KW - Metoclopramide

KW - Prolactin

KW - Thyrotropin

UR - http://www.scopus.com/inward/record.url?scp=0022492225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022492225&partnerID=8YFLogxK

U2 - 10.1159/000242591

DO - 10.1159/000242591

M3 - Article

C2 - 3768449

AN - SCOPUS:0022492225

VL - 50

SP - 141

EP - 146

JO - Neonatology

JF - Neonatology

SN - 1661-7800

IS - 3

ER -